| Prev Close | 4.09 |
| Day Low/High | 4.00 / 4.32 |
| 52 Wk Low/High | 3.85 / 36.65 |
| Avg Volume | 3.67M |
Mallinckrodt Plc (MNK)
4.08
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 84.01M |
| Market Cap | 343.60M |
| EPS | -42.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Bristol-Myers Squibb: A Long Idea for Aggressive Traders Only
BMY is not 'out of the woods' yet, but aggressive traders could probe the long side here.
More Mud on Johnson & Johnson?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Short-Selling Is Really Hard. Just Ask Citron Research
Examining the influential short-sellers' big winners and losers provides important insights into trading and investing.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
GoPro Is Among Seven Stocks Poised for a Reversal
These names are showing technical characteristics of either bullish or bearish reversal patterns.
Generic-Drug Stocks Are Looking Sickly
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.
Try This Pair of Biotech Trades
Teva and Mallinckrodt both lost over 50% of their value in 2017 and might catch some momentum here.
Closing Bell: Stocks Snap Two-Day Winning Streak; Apple to Add Amazon prime to Apple TV
Wall Street couldn't extend a record-breaking steak into a third session following the weekend terror attack in London.
Mallinckrodt Inquires Into Sale of Generic Drug Unit
Shares of drug maker Mallinckrodt were falling Wednesday afternoon
The Good, the Bad and the Ugly (EarlyAfternoon Edition)
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I want to spend some time with my family right after the close. So let's move...
Cramer: Reviewing S&P's Hit-and-Miss Parade
Even among the losers, buys are scarce.
Mallinckrodt Beats Estimates, Issues Downbeat Guidance
Shares of Mallinckrodt were lower on Tuesday, despite posting better than expected fourth-quarter revenue and profits.
5 Health Care Stocks Set to Bounce
These stocks are down some 20% over the last 30 months and look ripe for a rise.
Valeant Shares Tumble Before Clinton-Trump Faceoff
Andrew Left says cracking down on Big Pharma may be all that Hillary Clinton and Donald Trump have in common.
Andrew Left Says Trump and Clinton Agree on Just One Thing
Attacking Big Pharma price gougers may be all that unifies the candidates ahead of tonight's debate.
Trending Tickers: MYL, MNK, VRX, CHK, UA
Rising oil prices helped buoy U.S. markets Friday.
Big Pharma Has No Rx for Viral Social Media Reactions
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Andrew Left Says Mallinckrodt's Key Drug Could Be in Jeopardy
The drugmaker could be at risk as regulators begin to crack down on price hikes, Andrew Left says.
Mallinckrodt's Top Drug Could Go the Way of EpiPen
The drug that's helping boost the company's stock could become its biggest risk.
Cramer: 16 Things I Am Watching Right Now
Here are some things that could move stock prices today.
Trending Tickers: MNK, FTR, DISCA, CVS
Markets were falling as oil prices continued their two-month descent below $40 a barrel.
Trending Tickers: UAL, MNK, ENDP, BWA
Optimism that the United Kingdom will remain part of the EU was tempered by falling oil prices.
Mallinckrodt Needs More Medicine
A rally above $65 with strong volume is needed to change the direction of MNK.
Trader's Notebook: Mixing Coffee With Oil
Stalking Mallinckrodt for a short and Alcoa for a buy as well.
Mallinckrodt Is Robbing From the Health Care System, Says Andrew Left
One day after announcing a long position on Valeant, Andrew Left of Citron Research makes it clear he's still not a fan of Mallinckrodt.
Trader's Notebook: Three Names to Watch for Short Sellers
Short ideas on Abercrombie & Fitch, Apple and Mallinckrodt, plus an update on oil.
Cramer: Collateral Damage Is Giving These Stocks a Bad Name
But for the brave, they could offer a solid bottom-fishing opportunity.
Cramer: Nike's Stock Might Rebound After the Easter Weekend
The stock may go the way of all quickly judged stocks in this market.
